LUXEMBOURG--(BUSINESS WIRE)--Eurofins CDMO Alphora Inc. announces receipt in April 2022 of its Health Canada Standard Processing License issued within the Cannabis Act and Cannabis Regulations for its Oakville, Ontario Operations. This is complementary to
To accelerate clinical development of its best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL--(BUSINESS WIRE)--Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovativ
$21.6 million in net revenue for Q1 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS for 2022 Continued increases in LUPKYNIS™ (voclosporin) Patients on Treatment and Patient Start Forms; Steady Conversion Rates a
Nets CAD$15,480,780 cash in non-dilutive capital Current cash position of approximately CAD$50 million or approximately CAD $1.30 per share with only 38.4 million shares issued Profit realized on the sale of the non-core asset which was acquired by
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nutrien Ltd. (TSX and NYSE: NTR) announced today that Mr. Mark Thompson, Nutrien’s Executive Vice President, Chief Strategy and Sustainability Officer, will be speaking at the Goldman Sachs Industrials and Mater
- Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days - - Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 - LOS ANGELES & TORONTO--(BUSINESS WIRE)--#biotech--Kernel, a l
WINNIPEG, Manitoba--(BUSINESS WIRE)--Ag Growth International Inc. (TSX: AFN) (“AGI” or the “Company”) is pleased to announce the upsizing and amendment of our revolving credit facilities. AGI’s revolving credit facilities have been increased by
For the first time in the challenge’s history, Wageningen University & Research replaced all high-pressure sodium fixtures with a broad-spectrum, LED-only lighting system for its participants AUSTIN, Texas--(BUSINESS WIRE)--Fluence, a leading globa
- VBI’s 3-antigen adult HBV vaccine available in the U.S. as PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and now approved in the European Union (EU)/European Economic Area (EEA) as PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] - New
Ventus’ cGAS inhibitor to be studied as potential lupus treatment WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational platform to identify and d
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.